Background
==========

Peripheral artery disease (PAD) affects between 8--18 million people in the United States \[[@B1]\].Patients with PAD are known to have increased morbidity and mortality \[[@B2],[@B3]\]. Progression of PAD directly results in claudication, impaired walking, and amputation. The incidence of stroke, myocardial infarction, death or hospitalization is over 20% for patients with PAD \[[@B4]\]. Numerous medical guidelines recognize early detection of PAD as a critical factor both for mitigating PAD progression and improving risk management of cardiovascular disease \[[@B5]-[@B7]\].

PAD is characterized by impaired blood flow in the peripheral arteries due to atherosclerosis. Reduced blood flow and endothelial dysfunction are significant contributors to the progression of this disease, and the body of research on genetic factors involved is continually growing \[[@B8],[@B9]\]. Impaired angiogenesis and decreased capillary supply to skeletal muscle are seen in PAD and may be related to the symptoms and reduced functionality experienced by these patients. A recent trial showed that after participating in a supervised exercise training regimen, PAD patients experience an increase in microvasculature in the calf skeletal muscle (as measured by capillary density) and subsequent improvement in exercise capacity \[[@B10]\]. While possibly not the only mechanism for improved functionality, this study suggests the microvasculature involved may have a significant impact on the metabolic potential of working muscles in PAD patients. Research on potential treatments based on these mechanisms of action is ongoing, and early detection of PAD remains very important in the treatment course of patients with this disease.

Ankle-brachial index (ABI) testing is recommended by the US Preventative Services Task Force and American College of Cardiology for evaluating patients at risk for PAD \[[@B6],[@B7]\]. ABI testing in primary care settings can provide early diagnosis of PAD, allowing for earlier treatment \[[@B11]-[@B13]\]. There are several methods used to perform ABI measurement, with Doppler ABI being most common. However, adoption of Doppler-based ABI in primary care is limited. Previous studies have reported barriers to implementation, including the time required to conduct tests, the training needed, and the technical skills required \[[@B12],[@B14]\].

Automated ABI, either through oscilloscope or plethysmography, may be a more attractive option in primary care settings. This method is faster and easier, while maintaining accuracy \[[@B11],[@B12]\]; clinical results comparing alternative ABI methods to Doppler ABI have shown concordance above 90% \[[@B15]-[@B18]\]. This study evaluated the use of a specific plethysmography, or digital ABI, device in primary care settings to determine if results were consistent with known PAD population characteristics.

Methods
=======

A device-specific, voluntary data registry was created to capture physician reported results on adult patients. A standardized, self-administered questionnaire was used to identify PAD signs, symptoms and cardiovascular risk factors in patients presenting to primary care practices (see Additional file [1](#S1){ref-type="supplementary-material"}). Patients with signs, symptoms and/or risk factors for PAD were then tested with a digital ABI device (FloChec™ manufactured by Semler Scientific, Inc, Portland Oregon United States) to evaluate flow obstruction in each lower extremity compared to the corresponding upper extremity. All data was de-identified. ABI results, PAD signs and symptoms, and cardiovascular risk factors were recorded and input into a central database for analysis.

The FloChec™ device is a blood volume plethysmography technology that received Food and Drug Administration (FDA) clearance for commercial use in the United States in 2010. The FloChec™ system consists of a sensor coupled with an infrared light emitting diode (LED) within a pulse-oximetry style clamp, and an attached portable computer that runs proprietary software. Measurements with FloChec™ are performed bilaterally on the lower and upper extremities by placing the clamp on one digit of each extremity in sequential fashion. During measurement, the LED transmits light into the digit, and the sensor measures reflected/scattered light. The blood volume in the digit affects the amount of returning light, and these blood volume waveforms are recorded and analyzed by the device. Blood flow index (BFI), a measure of proximal patency, is calculated by a proprietary algorithm for each extremity. Comparison of BFI in the lower extremity to BFI in the upper extremity produces the ratio known as digital ABI. Four pulse waveforms, four blood flow indices, and two ABI results are provided in a standard report for each patient. A digital ABI result of \<0.93 indicates the presence of flow obstruction.

Binary variables were created for each sign, symptom, or risk factor based on the corresponding questionnaire response. A subject was considered to have claudication if the response to question one was "no" and the response to questions two and three was "yes". Standard summary statistics were calculated for study variables of interest. For continuous variables, statistics included the number of observations (N), mean, standard deviation, and 95% confidence interval. Categorical variables were summarized in frequency distributions. Prevalence odds ratios with 95% confidence intervals were calculated for each categorical variable of interest, comparing the PAD positive group to the PAD negative group. A multivariate regression examining the effect of risk factors, signs and symptoms, sex, and age on ABI was conducted. To identify important predictors, a step-wise selection procedure that included all possible predictors collected in the study and all possible two-way interactions was executed. Terms were allowed to enter the model with a significance level ≤0.3 and were removed if they had a significance level ≥0.1. Statistical analyses were conducted in SAS version 9.3 (SAS Institute, Cary, N.C.), and graphics were produced in R version 2.11.1. Because the technology used in this study has been commercially cleared in the US and only de-identified data was collected, ethics committee approval was not required.

Results
=======

A total of 19 medical practices throughout the United States examined 632 patients with the FloChec™ system. Table [1](#T1){ref-type="table"} provides a summary of practice types that participated. These patients were tested based on results of a self-administered questionnaire that indicated risk factors, signs, and/or symptoms suspicious of PAD. Data was provided on digital ABI results for all patients. Of the 632 patient questionnaires collected, 56 had one or more missing data fields. These patients were included in analysis. The number of completed fields used in each calculation is provided in the tables. Population characteristics are provided in Table [2](#T2){ref-type="table"}. The average age of the population tested was 67.2±13.8 years, and 38.0% of the population was male (95% CI 33.7%-42.3%). Of the patients tested, 94.7% had risk factors, signs and/or symptoms suspicious for PAD, and 20.3% (95% CI 17.1%-23.6%) presented with claudication.

###### 

Types of participating clinical sites

  **Practice type**          **Number of sites % (n/N)**   **Number of patients tested % (n/N)**
  ------------------------- ----------------------------- ---------------------------------------
  General/Family practice           57.9% (11/19)                     52.2% (349/632)
  Podiatry practice                 31.6% (6/19)                      31.3% (198/632)
  Other                             10.5% (2/19)                      13.4% (85/632)

###### 

Summary of study population demographics, signs/symptoms, and risk factors

  **Measure**                **All subjects**   **PAD negative subjects**   **PAD positive subjects**                               
  ------------------------- ------------------ --------------------------- --------------------------- -------------- ------------- --------------
  Age (years)                  67.2 ± 13.8             66.1, 68.3                  67.1 ± 13.9           65.9, 68.2    68.2 ± 12.9    65.2, 71.1
  \(627\)                        \(551\)                 \(76\)                                                                     
  Age group (years)                                                                                                                        
     \<50                         10.7%                8.3%, 13.1%                    10.7%             8.1%, 13.3%       10.5%      3.6%, 17.4%
  (67/627)                       (59/551)                (8/76)                                                                     
     50-59                        17.7%               14.7%, 20.7%                    18.5%             15.3%, 21.8%      11.8%      4.6%, 19.1%
  (111/627)                     (102/551)                (9/76)                                                                     
     60-69                        25.5%               22.1%, 28.9%                    25.0%             21.4%, 28.7%      28.9%      18.8%, 39.1%
  (160/627)                     (138/551)                (22/76)                                                                    
     70+                          46.1%               42.2%, 50.0%                    45.7%             41.6%, 49.9%      48.7%      37.4%, 59.9%
  (289/627)                     (252/551)                (37/76)                                                                    
  Male                            38.0%               33.7%, 42.3%                    36.6%             32.0%, 41.1%      47.1%      35.2%, 58.9%
  (190/500)                     (158/432)                (32/68)                                                                    
  Claudication                    20.3%               17.1%, 23.6%                    19.7%             16.3%, 23.1%      25.0%      15.0%, 35.0%
  (122/600)                     (104/528)                (18/72)                                                                    
  Discolored/blue legs            21.6%               18.3%, 24.8%                    20.6%             17.2%, 24.0%      28.4%      18.1%, 38.7%
  (133/617)                     (112/543)                (21/74)                                                                    
  Non-healing wound               11.4%                8.9%, 13.9%                    11.0%             8.4%, 13.6%       14.5%      6.6%, 22.4%
  (71/622)                       (60/546)                (11/76)                                                                    
  At least 1 sign/symptom         42.1%               38.2%, 46.0%                    41.2%             37.1%, 45.3%      48.7%      37.4%, 59.9%
  (264/627)                     (227/551)                (37/76)                                                                    
  High cholesterol                61.5%               57.6%, 65.3%                    61.5%             57.3%, 65.6%      61.6%      50.5%, 72.8%
  (375/610)                     (330/537)                (45/73)                                                                    
  Hypertension                    72.5%               69.0%, 76.1%                    73.0%             69.2%, 76.7%      69.4%      58.8%, 80.1%
  (444/612)                     (394/540)                (50/72)                                                                    
  Diabetes                        47.3%               43.4%, 51.3%                    46.5%             42.3%, 50.7%      53.3%      42.0%, 64.6%
  (291/615)                     (251/540)                (40/75)                                                                    
  Smoking history                 40.1%               36.3%, 44.0%                    38.7%             34.6%, 42.8%      50.7%      39.4%, 62.0%
  (250/623)                     (212/548)                (38/75)                                                                    
  Stroke/TIA                      13.2%               10.6%, 15.9%                    11.5%             8.8%, 14.2%       26.0%      16.0%, 36.1%
  (82/620)                       (63/547)                (19/73)                                                                    
  CAD                             33.3%               29.6%, 37.0%                    31.6%             27.7%, 35.5%      45.9%      34.6%, 57.3%
  (206/618)                     (172/544)                (34/74)                                                                    
  Number of risk factors                                                                                                                   
     0                             7.8%                5.7%, 9.9%                     8.2%              5.9%, 10.5%       5.3%       0.2%, 10.3%
  (49/626)                       (45/550)                (4/76)                                                                     
     1                            13.9%               11.2%, 16.6%                    13.8%             10.9%, 16.7%      14.5%      6.6%, 22.4%
  (87/626)                       (76/550)                (11/76)                                                                    
     2                            23.3%               20.0%, 26.6%                    24.5%             20.9%, 28.1%      14.5%      6.6%, 22.4%
  (146/626)                     (135/550)                (11/76)                                                                    
     3+                           55.0%               51.1%, 58.8%                    53.5%             49.3%, 57.6%      65.8%      55.1%, 76.5%
                                (344/626)                                           (294/550)                            (50/76)           

Twelve percent (76/632) of patients had an abnormal FloChec™ result (digital ABI \<0.93). The frequency of abnormal left leg result, abnormal right leg result, and abnormal result for both legs was 4.9% (31), 2.8% (18), and 4.3% (27), respectively. Of those with digital ABI \<0.93 (PAD positive group), the mean age was 68.2±12.9 years and 47.1% (95% CI 35.2%-58.9%) were male. In this group, hypercholesterolemia, hypertension, and coronary artery disease (CAD) were reported in 61.6% (95% CI 50.5%-72.8%), 69.4% (95% CI 58.8%-80.1%), and 45.9% (95% CI 34.6%-57.3%) of patients, respectively. A self-reported history of smoking was found in 50.7% (95% CI 39.4%-62.0%) of the abnormal digital ABI patients. Figure [1](#F1){ref-type="fig"} shows the prevalence of positive PAD result by sex and age group. Patients with digital ABI \<0.93 were more likely to be in age groups 60--69 and 70+ (28.9% and 48.7%, respectively) than in age groups \<50 and 50--59 (10.5% and 11.8%, respectively).

![Prevalence of PAD by sex and age group in this study population.](1756-0500-6-404-1){#F1}

Of the 122 patients with symptoms of claudication, 18 (14.8%) tested positive for flow obstruction on digital ABI measurement while 54 (11.3%) of the patients without claudication (asymptomatic) tested positive. There was no difference observed in digital ABI value between symptomatic and asymptomatic patients; the mean digital ABI and standard deviation was 0.95±0.13 and 0.96±0.12 for those with claudication (N=122) and without claudication (N=478), respectively.

Table [3](#T3){ref-type="table"} displays prevalence odds ratios for each measure examined. Several risk factors were statistically significantly more common in the PAD positive group than the PAD negative group; these included smoking history (OR 1.63, 95% CI 1.00-2.64), stroke/transient ischemic attack (TIA) (OR 2.70, 95% CI 1.51-4.85), and CAD (OR 1.84, 95% CI 1.12-3.01). From the multivariate analysis, two predictors, hypertension (p=0.018) and stroke/TIA (p=0.0360), emerged as having the most influence on ABI.

###### 

Unadjusted prevalence odds ratios (PAD positive group compared to PAD negative group)

  **Measure**              **OR (95% CI)**    **P-value**
  ---------------------- ------------------- -------------
  Age                     1.01 (0.99, 1.03)      0.391
  Male                    1.54 (0.92, 2.58)      0.099
  Claudication            1.36 (0.76, 2.42)      0.295
  Discolored/blue legs    1.52 (0.88, 2.63)      0.131
  Non-healing wound       1.37 (0.69, 2.74)      0.372
  High cholesterol        1.01 (0.61, 1.67)      0.975
  Hypertension            0.84 (0.49, 1.44)      0.530
  Diabetes                1.32 (0.81, 2.14)      0.266
  Smoking history         1.63 (1.00, 2.64)      0.049
  Stroke/TIA              2.70 (1.51, 4.85)     \<.001
  CAD                     1.84 (1.12, 3.01)      0.015

Discussion
==========

In this study, primary care practices evaluated patients suspected to have PAD based on history and physical exam and performed digital ABI measurements. Of these patients, 12% were confirmed to have obstructed flow based on the criteria of the digital ABI test. These results are similar to previous findings using other ABI methods. Reported prevalence of PAD ranges from 4.3% to 16.8%; with age adjusted prevalence of 12% \[[@B19]-[@B22]\]. Selvin and Erlinger reported an overall frequency of 4.3%, with a significant increase in prevalence among those 60--69 (4.7%) and over 70 (14.5%) years old \[[@B22]\]. As depicted in Figure [1](#F1){ref-type="fig"}, our study demonstrated similar trends, with patients 60 years and older yielding the highest frequency of obstructed flow. Characteristics of the patients with obstructed flow identified by digital ABI in this study population were consistent with other PAD studies with respect to mean age, proportion of males, and positive limbs (right, left, or both) \[[@B19],[@B20],[@B22]\].

The prevalence of risk factors in patients with obstructed flow measured by FloChec™ was consistent with previous findings evaluating other techniques. Several studies, including REACH (the largest international PAD registry study conducted to date), report rates of hypercholesterolemia, hypertension, and diabetes (66.7%, 81.0% and 44.6% respectively) similar to or higher than our findings (61.6%, 69.4% and 53.3%, respectively) \[[@B19]\]. Selvin and Erlinger also reported similar rates (60.6%, 73.6% and 26.4%, respectively) \[[@B22]\]. The prevalence of PAD in patients with greater than three risk factors was also concurrent. This study found 65.8% of patients with flow obstruction had three or more risk factors, compared to 60-80% of populations previously studied \[[@B19],[@B20],[@B22]\].

Earlier accurate PAD diagnosis and treatment initiation could potentially greatly improve clinical outcomes; as indicated by Duscha et al., there is a growing body of research around exercise training as therapeutic intervention to promote angiogenesis of the microvasculature in the lower extremity skeletal muscle and improve exercise tolerance \[[@B23]\]. Recent evidence also suggests that a particular calcium/calmodulin-dependent kinase (*CaMK4*) may have an important role in blood pressure regulation through the control of endothelial nitric oxide synthase (eNOS) activity via phosphorylative events. In this study, loss of the *CaMK4* gene resulted in endothelial dysfunction, hypertension, and related complications in mice. In humans, a significant correlation was found between reduced expression of a *CaMK4* polymorphism and higher blood pressure levels among hypertensive patients \[[@B9]\]. Another study on the in vivo effects of a vascular endothelial growth factor (VEGF) mimetic (called QK) offered a potential new method for examining angiogenesis triggered by VEGF receptors. The proteins involved are important for capillary formation and organization and could have large implications for treatment of conditions like chronic ischemia \[[@B8]\]. While research on the etiologies and mechanisms of action of PAD continues, our study supports correlations observed between clinical manifestations and impaired blood flow Figure [1](#F1){ref-type="fig"}. Interestingly, TIA/stroke (another clinical outcome of endothelial dysfunction) was a statistically significant characteristic in the group found positive for flow obstruction in this study.

Many patients with PAD are asymptomatic and are not referred to vascular specialists when evaluated in the primary care practice. These patients do not begin prophylactic therapies, such as walking, as early as possible. Hirsch et al. found that only 11% of PAD patients had symptoms of claudication \[[@B11]\]. The results of our study suggest slightly higher rates of claudication in the presence of PAD (25%); however, the majority of patients in this group were asymptomatic. Given the increased morbidity and mortality in asymptomatic PAD, specifically without concomitant CAD, and the reported benefits of early treatment, digital ABI could potentially provide early detection and improved disease management \[[@B11]\]. The medical literature indicates that abnormal ABI results are highly concordant with angiographic diagnosis of PAD, supporting the use of ABI or digital ABI in the primary care setting as a more objective assessment of the need for referral to a vascular specialist \[[@B24]\].

Given the severe primary and secondary consequences of delayed diagnosis of PAD, early evaluation and detection is critical. While ABI measurement has long been recognized as an acceptable means of evaluation, traditional Doppler ABI may not be conducive to the primary care setting because this method is time consuming and requires specialized vascular technologists to be performed properly \[[@B14]\]. Development of ABI devices that are easy to use, inexpensive, accurate and less time-consuming can potentially make PAD testing in the primary care practice feasible. The FloChec™ measurement is performed in a few minutes by a medical assistant under the direct supervision of a primary care physician trained on the technique.

Previous studies have found that 46% of patients referred to vascular centers based on clinical suspicion alone were without significant PAD \[[@B13]\]. Our study showed similar results; 41% of patients with a result negative for PAD had presented with at least one sign or symptom. As supported by our research, a significant population presents with clinical symptoms or risk factors that may not be attributable to PAD and who might not require referral to a vascular specialist.

This study had several limitations. The registry was designed to collect and describe digital ABI results and patient history retrospectively, without pre-defined parameters. One major limitation was the lack of direct comparison to Doppler ABI/definitive diagnostic techniques for each observation. Doppler ABI data was not captured as part of the registry database, but is of primary importance for currently ongoing and future studies evaluating this new technology. The passive data collection method used meant that not all data on demographics, signs/symptoms, and risk factors could be collected for all patients. Of the observations provided, 8% had one or more missing data field. All analyses were based on the number of fields completed for each variable of interest.

This was an open data registry; therefore, the clinical sites that provided data did so voluntarily. The variation of clinical care settings allowed for data to be collected in "real world" settings, where a wide variety of patients were tested with the device. As a consequence of this pragmatic approach, the data collection process did not include additional controls or data monitoring. Risks of this method included missing data and possible errors during case report form completion. No inclusion or exclusion criteria were applied; therefore, the data set may be biased in either direction. However, given the large number of patients tested and prevalence rates similar to other studies, the risk of patient selection bias is low. Lastly, this study lacked follow up or definitive diagnostics; therefore, this study does not address sensitivity and specificity of the digital ABI test. Although the results are consistent with previous population-based studies; additional studies are warranted to fully evaluate this technology.

Conclusions
===========

The results of this large, population-based study support the use of a digital ABI device (FloChec™) using blood volume plethysmography technology for early evaluation and detection of patients at risk for PAD. Compared to Doppler ABI, digital ABI devices enable PAD evaluation in primary care settings and may allow for earlier detection of the disease. Of importance, the Medicare population (over 65 years of age) may benefit most from early evaluation with digital ABI in primary care settings. Further studies are needed to determine the benefit to other high risk populations, such as diabetics, and to evaluate the correlation of digital ABI results using this device with definitive diagnostic techniques.
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